Randomised, split-face study of a dermocosmetic cream containing Sphingobioma xenophaga extract and Neurosensine
dermocosmetic
erythema
external factors
rosacea
sensitive skin
skin barrier
Journal
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
ISSN: 1600-0846
Titre abrégé: Skin Res Technol
Pays: England
ID NLM: 9504453
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
21
03
2024
accepted:
24
04
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
ppublish
Résumé
Rosacea is a chronic inflammatory skin condition associated with erythema, inflammation and skin sensitivity. To assess the benefit of a dermocosmetic cream (DC cream) containing Sphingobioma xenophaga extract and soothing agent in adult females with rosacea-associated erythema and sensitive skin. During phase 1, DC was applied twice daily on the randomized half-face and compared to usual-skincare (USC) for 28 days. During phase 2, DC was applied on the full face twice daily for 56 days. Clinical, instrumental and skin sensitivity assessments were performed at all visits; demodex density (standardized skin surface biopsy (SSSB) method) was performed at baseline and D28, quality of life (QoL) was assessed using the stigmatization questionnaire (SQ), Rosacea Quality of Life index (ROSAQoL) and Dermatology Life Quality Index (DLQI) at baseline and D84. At D28, a significant benefit of DC over USC was observed for erythema, tightness, burning and stinging (all p ≤ 0.05), erythema measured by chromameter (p < 0.01), corneometry and transepidermal water loss (p < 0.0001 and p < 0.05, respectively), skin sensitivity (p < 0.001) and significant reduction of mean demodex density (p < 0.05) on the DC side. At D84, DC significantly (all p < 0.05) improved clinical signs and symptoms on both sides of the face compared to baseline; SQ, ROSAQoL and DLQI scores improved by 40.4%, 25.0% and 55.7%, respectively compared to baseline. Tolerance was excellent. DC significantly improved erythema, skin sensitivity, demodex count, QoL and feeling of stigmatization of subjects with rosacea and is very well tolerated.
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13735Informations de copyright
© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.
Références
Thiboutot D, Anderson R, Cook‐Bolden F, et al. Standard management options for rosacea: the 2019 update by the national rosacea society expert committee. J Am Acad Dermatol. 2020;82(6):1501‐1510.
Cardwell LA, Nyckowski T, Uwakwe LN, Feldman SR. Coping mechanisms and resources for patients suffering from rosacea. Dermatol Clin. 2018;36(2):171‐174.
Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017;31(1):163‐168.
Powell FC. The histopathology of rosacea: ‘where's the beef?’. Dermatology. 2004; 209:173‐174.
Lee SG, Kim J, Lee YI, Choi YS, Ham S, Lee JH. Cutaneous neurogenic inflammation mediated by TRPV1‐NGF‐TRKA pathway activation in rosacea is exacerbated by the presence of Demodex mites. J Eur Acad Dermatol Venereol. 2023;37(12):2589‐2600.
Li M, Tao M, Zhang Y, Pan R, Gu D, Xu Y. Neurogenic rosacea could be a small fiber neuropathy. Front Pain Res (Lausanne). 2023;4:1122134.
Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26(8):659‐667.
Hari A, Flach TL, Shi Y, Mydlarski PR. Toll‐like receptors: role in dermatological disease. Mediators Inflamm. 2010;2010:1.
Damiani G, Gironi LC, Grada A, et al. COVID‐19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi‐center, real‐life, telemedical, and observational prospective study. Dermatol Ther. 2021;34(2):e14848.
Chiriac AE, Wollina U, Azoicai D. Flare‐up of Rosacea due to face mask in healthcare workers during COVID‐19. Maedica (Bucur). 2020;15(3):416‐417.
Gueniche A, Nielsen M. Introduction to probiotic fractions and Vichy volcanic mineralizing water: two key ingredients for stressed skin. J Eur Acad Dermatol Venereol. 2022;36 Suppl 2:3‐4.
Boo YC. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants. 2021;10(8):1315.
Di Paolo CT, Diamandis EP. Prassas I. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. Crit Rev Clin Lab Sci. 2021;58(1):1‐16.
Two AM, Del Rosso JQ. Kallikrein 5‐mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014;7(1):20‐25.
Berardesca E, Farage M, Maibach H. Sensitive skin: an overview. Int J Cosm Sci. 2013;35(1):2‐8.
Yun CH, Yun JH, Baek JO, Roh JY, Lee JR. Demodex mite density determinations by standardized skin surface biopsy and direct microscopic examination and their relations with clinical types and distribution patterns. Ann Dermatol. 2017;29(2):137‐142.
Tannus FC, Picosse FR, Soares JM, Bagatin E. Rosacea‐specific quality of life questionnaire: translation, cultural adaptation and validation for Brazilian Portuguese. An Bras Dermatol. 2018;93(6):836‐842.
Van Beugen S, Schut C, Kupfer J, et al. Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries. Acta Derm Venereol. 2023;103:adv6485.
Finlay AY, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210‐216.
Ivanic MG, Oulee A, Norden A, Javadi SS, Gold MH, Wu JJ. Neurogenic rosacea treatment: a literature review. J Drugs Dermatol. 2023;22(6):566‐575.
Baldwin H, Alexis AF, Andriessen A, et al. Evidence of barrier deficiency in rosacea and the importance of integrating OTC skincare products into treatment regimens. J Drugs Dermatol. 2021;20(4):384‐392.